(NASDAQ: SAVA) Cassava Sciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.5%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.87%.
Cassava Sciences's earnings in 2026 is -$106,031,000.On average, 3 Wall Street analysts forecast SAVA's earnings for 2026 to be -$60,114,346, with the lowest SAVA earnings forecast at -$57,756,920, and the highest SAVA earnings forecast at -$61,882,415.
In 2027, SAVA is forecast to generate $443,466,485 in earnings, with the lowest earnings forecast at $426,075,643 and the highest earnings forecast at $456,509,617.